2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.
Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastases.
The most important unmet challenge need in the treatment of these patients is better biomarkers, states Ross. Having biomarkers would allow physicians to know which patients will benefit from immunotherapy regimens.
Additionally, biomarkers will help determine who will develop a resistance to immunotherapy so alternative therapies can be identified for the patient, explains Ross.
Related Content: